Introduction
Osteoporosis is now a major health problem worldwide, in particular due to general population aging. An important cause of osteoporosis is estrogen deficiency that results in excessive bone loss in postmenopausal women. Diverse conditions such as bone metastases, lack of physical activity, disability and inflammation also provoke osteoporosis. Although the mechanisms of these diseases are distinct, excessive activity of osteoclasts (OCs) is a common feature and hallmark of osteoporosis (1) . OCs, the major bone resorbing cells, are derived from mononuclear precursors of the monocyte/macrophage lineage such as bone marrow macrophages (BMMs). In response to the cytokines RANKL (receptor activator of NF-kappaB ligand) and M-CSF, monocyte precursors differentiate into preOCs that ultimately fuse to form polykaryons with the capacity to resorb mineralized substrates such as bone (2) . To initiate bone resorption, OCs polarize and undergo extensive morphological changes to form an actin ring, also known as the sealing zone (3) . This OC specific adhesion structure is composed of densely packed podosomes (4) . It surrounds the ruffled border, a differentiated region of the plasma membrane that secretes protons and proteases at the bone contact. This is the actual site of bone resorption (5) . The activation of RANK receptor by RANKL elicits a complex transcriptional program during OC differentiation. The master OC transcription factor NFATc1 regulates many OC specific genes, in particular ATP6v0d2 and D C-STAMP, involved in precursor fusion, and Acp5, Ctsk, Src and ITGB3, essential for bone resorption (6) . At the bone surface, OCs cycle between resorptive and migratory phases.
Assembly and disassembly of the sealing zone requires profound remodeling of the actin cytoskeleton (7) , regulated by adhesion signaling molecules, including Src, Pyk2 and p130Cas, downstream of integrin !vß3 (8) . As major cellular regulators of actin organization, Rho GTPase signaling pathways are also essential players in sealing zone assembly (9) . Rho GTPases cycle between inactive GDP-bound and active GTP-bound states. In their active form they bind to effector proteins and engage numerous signaling pathways. Efficient nucleotide replacement requires guanine nucleotide exchange factors (GEFs) that catalyze activation of Rho GTPases (10) . These GEFs fall into two families: Dbl-and Dock-proteins.
The Dock family of GEFs comprises 11 Dock1-(also known as Dock180-) related proteins in mammals (11, 12) . Docks are characterized by a unique DHR (or CZH)-2 domain, which catalyzes nucleotide exchange on Rac1 or Cdc42, and a DHR-1 domain that localizes the GEFs to phosphatidylinositol (3, 4, 5) phosphates enriched membranes. Dock1, Dock2 and Dock5 also contain an SH3 domain at the N-terminus and a poly proline domain at the Cterminus. Through these domains, Dock1 interacts with CrkII, Crk-L and ELMO proteins and promotes Rac1 activation for efficient actin remodeling, cell migration and adhesion, myoblast and macrophage fusion (12) (13) (14) (15) .
In a previous study, we found that RANKL activates the transcription of Dock5 (16) . In addition, Dock5 is among the membrane-associated proteins most significantly overexpressed in OCs as compared to macrophages (17) . Here, we tested the idea that Dock5 could be a central player in the control of OC cytoskeleton dynamics and biological activity. We demonstrate that Dock5 is essential for formation of the sealing zone and consequently for bone resorption by OCs. In addition, interfering with Dock5 expression abrogated Rac1 activation and impaired OC integrin-mediated adhesion. Likewise, blocking Dock5-mediated activation of Rac1 using a novel small biochemical inhibitor strikingly decreased OC resorption activity. Importantly, mice bearing a genetic deletion of Dock5 have increased trabecular bone mass, in agreement with a role of this GEF in bone resorption. Our findings therefore identify a novel molecular mechanism that regulates actin dynamics for sealing zone assembly in OCs. They further highlight Dock5 as a potential target for novel antiosteoporotic treatments.
M aterials and M ethods
Mice.
Dock5 -/mice were previously described (14) . Mice used were 4 to 8-week-old and were maintained at the animal facilities of the CNRS in Montpellier and of the IRCM in Montreal.
Histological analyses.
Femurs of 8-week old mice were fixed for one week in 10% formalin in PBS, embedded in Historesin (Leica), 7 µm sections stained with von Kossa and counterstained with von Gieson.
Alternately, bones were decalcified in 10 % EDTA for 10 days, embedded in paraffin and 4.5 µm sections stained for TRAP activity and counterstained with a nuclear fast red. Measures were done in a standard zone in distal femur situated 250 µm from the growth plate excluding the primary spongiosa. Bone volume, total volume, OC numbers and bone perimeters were measured in the same region of interest on three adjacent slides, using Bioquant OSTEO II (Bioquant Image Analysis).
Production of OCs and osteoblasts.
BMMs were isolated from long bones of 4-to 8-week-old animals as described (16) and OCs obtained by culturing BMMs with RANKL (100 ng/ml) and M-CSF (10 ng/ml) (Peprotech) for 5 days. RAW264.7 cells were grown for 5 days with RANKL (50 ng/ml) to obtain OCs.
For resorption, OCs were differentiated in multiwell chambers or on coverslips coated with calcium phosphate (Osteologic Biocoat, BD Bioscience) or in 96-well plates containing a bovine bone slice (IDS Nordic Bioscience). Mesenchymal stem cells (MSCs) were isolated from mouse bone marrow and grown as described (18) . Osteogenesis was induced by culture at low density (3 X 10 4 cells in 6-well plates) for 21 days in osteogenic medium (DMEM supplemented with 10 % FBS, 2 mM glutamine and 0.05 mM ascorbic acid), supplemented with 3mM NaH2PO4 for mineralization assays. Osteoblasts were characterized by alizarin red S staining of the secreted calcified extracellular matrix as previously described (18) .
Microscopy, immunofluorescence and TRAP labeling.
OCs were fixed and stained for DNA, actin or vinculin or TRAP as described (16, 19) . Antivinculin antibody (Sigma) was revealed with Alexa Fluor 546-conjugated secondary antibody and actin stained with Alexa Fluor 360 or 488-conjugated phalloidin (Invitrogen). where they were counted automatically using a Cellomics Arrayscan VTI (Thermo Scientific). For scanning electron microscopy, OCs on bone slices were fixed in PBS containing 3% glutaraldehyde and post-fixed with 1% OsO4 . After alcohol dehydration, OCs were dried in hexamethyldisilazane (Acros Organics, NJ, USA) for 2! min, coated with Goldpalladium and observed using a Hitachi S4000 scanning microscope at 10! kV.
Preparations were mounted in

Adhesion assays.
OCs differentiated in 96-well plates were incubated for 5 minutes in PBS supplemented or not with 0.25 mM EDTA. Wells were then rinsed with <*D,' EF&%,' 2(514&%' G1(0' >H@I' J.B2(5!' violet, lysed and OD595 was measured as described (19) . Each condition was performed in triplicate wells.
Plasmid DNAs.
Yeast expression vectors for Rac1 and Kinectin (20, 21) and GFP-fused TrioN (22) were reported previously. The obtain full length Dock5 cDNA, BamH1-Kpn1 fragment of RIKEN clone E130320D18 (nucleotides 249 to 1,913 of Dock5 mRNA), was fused to the Kpn1-Not1 fragment of IMAGE clone 30106676 (nucleotides 1,914 to 6,461 of Dock5 mRNA). The whole was fused to GFP and was inserted into pMXs-puro (23), a gift from Dr Kitamura, Tokyo, Japan. Dock5 DHR2 domain (aminoacids E1119 to L1667) was cloned into pEGFP (Clontech) or myc tagged in pRs426Met (21) . Dock5 and firefly luciferase shRNA expression vectors were described previously (16) as well as methods to produce and use retroviruses (16, 19) .
RT-PCR and primers.
RT-PCR analyses were performed as described (19) Diego, CA) (25) . Growth curves were established by measuring OD600. Inhibitors were selected for their ability to inhibit selectively growth acceleration in histidine-free medium conferred by Dock5-DHR2 expression without affecting growth in histidine-supplemented medium.
Statistical analyses.
Statistical significances were determined using Mann-Whitney non-parametrical test.
RESULTS.
Dock5 is a Rac1 GEF associated with OC adhesion structures.
We previously identified Dock5 as a RhoGEF gene strongly induced during RANKLstimulated osteclastogenesis in RAW264.7 cells and BMMs (16) ( Figure 1A ). Purified antibodies directed against the C-terminal end of Dock5 (14) Figure 1F ).
Dock5 is essential for OC function in vitro.
To investigate the role of Dock5 in OC biology, we downregulated Dock5 in RAW264.7 cells using shRNAs (16) . Whereas complete silencing of Dock5 leads to massive detachment of cells around day 3 of differentiation (16), lower retroviral concentrations leading to moderate silencing of Dock5 protein ( Figure S1A ) allows efficient formation of TRAP positive mutlinucleated cells in response to RANKL ( Figure S1B ). Strikingly, these OCs seeded on calcium-phosphate-coated substrates do not form sealing zones ( Figure S1C ). Accordingly, they do not resorb the mineral substrate ( Figure S1D ). Consistently, OCs derived from shDock5-expressing BMMs exhibit very few and small sealing zones ( Figure   S1E ) and have reduced bone resorbing activity ( Figure S1F ). This suggests that Dock5 is involved in formation of the sealing zone and then, in bone resorption by OCs.
To further study the physiological role of Dock5 in OCs, we differentiated OCs from primary BMMs isolated from Dock5 +/+ and Dock5 -/mice (14) . Dock5 -/-BMMs differentiate into OCs defined as TRAP positive multinucleated cells (Figure 2A ). But Dock5 -/-OCs fail to assemble sealing zones when seeded on calcium-phosphate substrates ( Figure 2B -C) and they do not resorb the calcium-phosphate mineral substrate (not shown). Electron micrograph of bone slices seeded with Dock5 -/-OCs showed that they can adhere on bone, but they were never found associated with a resorption pit ( Figure 2D ). Staining with WGA lectin showed that bone slices seeded with Dock5 -/-OCs have very few and small resorption pits ( Figure   2E ). Measurement of degradation products of C-terminal telopeptide of type I collagen (CTx) production in the culture medium indeed confirmed that Dock5 -/-OCs are defective for bone resorption ( Figure 2F ).
These results characterize Dock5 as being essential for the formation of OC sealing zone and subsequent bone resorption.
Dock5 is necessary for Rac1 and p130Cas activation in OCs.
We next evaluated the importance of Dock5 for RANKL induced expression of osteoclastic marker genes exploiting Dock5 +/+ and Dock5 -/-BMMs. Real-time Q-PCR did not reveal any defect in the expression of the 12 genes tested ( Figure 3A ). In particular, ITGB3, Src and Vav3 that are involved in sealing zone formation are expressed at normal levels. We also noticed that Dock5 deficiency does not induce a compensatory overexpression of Dock1
or Dock2, the closest Dock5 paralogs ( Figure 3B ). Thus, suppression of Dock5 does not appear to prevent the establishment of the OC specific transcriptional program.
We then investigated how the absence of Dock5 may impact on the activation of Rac1 in OCs. M-CSF regulates OC cytoskeleton (28) and induces rapid activation of Rac1 leading to the phosphorylation of Erk1/2 (29, 30) . Integrin !vß3 stimulation by adhesion of OC onto vitronectin also activates Rac1 (29, 31) . In the absence of Dock5, we found that M-CSF induces normal Rac1 activation and Erk1/2 phosphorylation ( Figure 3C -D) and adhesion stimulated activation of Rac1 is not affected ( Figure 3E ).
We then looked at the steady state level of Rac1 activity in adherent OCs under no stimulation. In this case, active Rac1 pull down assays showed a strong reduction in Rac1 activity in OCs derived from Dock5 -/-BMMs or from RAW264.7 cells expressing Dock5 shRNAs ( Figure 4A-B ). Dock5 -/-OCs exhibited very irregular shapes on plastic ( Figure 4C) as confirmed by significantly reduced circularity ( Figure 4D ). Furthermore, Dock5 -/-OCs are less resistant to detachment from the substrate upon EDTA treatment ( Figure 4E ). These results show that in the absence of Dock5, OCs have low levels of Rac1 activity associated with spreading and adhesion defects.
We next investigated candidate signaling molecules known to participate in the control of OC adhesion that could be linked to Dock5 and Rac1 signaling. The adaptor protein p130Cas
is involved in actin organization in OCs (32) (33) (34) . Dock1 is known to stimulate signaling from the CrkII-p130Cas complex by increasing p130Cas tyrosine phosphorylation (35) , which in turn stimulates Rac1 activation by the GEF (36) . Dock5 was shown to control epithelial cell spreading through its binding to CrkII (37) . The overall tyrosine phosphorylation profile in adherent OCs was not modified in the absence of Dock5 ( Figure 4F Figure 4G -H), which is known to prevent binding of CrkII to p130Cas (38) . Conversely, phosphorylation of Pyk2, a partner of p130Cas in OCs involved in sealing zone formation (39, 40) , remained unchanged in the absence of Dock5 ( Figure 4G -H).
Taken together, these results suggest that the absence of Dock5 in OCs leads to adhesion defects associated with defective activation of Rac1 and p130Cas.
A chemical inhibitor of Rac1 activation by Dock5 hinders OC bone resorbing activity.
To confirm the essential role of Rac1 activation by Dock5 in the resorption process, we sought for a chemical inhibitor of Dock5 exchange activity active in cell cultures. We therefore took advantage of a yeast-based assay that we have developed (20, 22) . We constructed a yeast strain where Rac1 activation by Dock5 DHR2 induces the expression of the his3 reporter gene ( Figure 5A ), which leads to faster yeast growth in Histidine deprived medium ( Figure 5B ). We screened a library of 2,640 heterocyclic commercial chemical compounds as described previously (22) for molecules able to inhibit growth of Dock5 DHR2-expressing yeasts in Histidine deprived medium without affecting growth in Histidine complemented medium. Thus we identified C21: N-(3,5-dichlorophenyl)benzenesulfonamide ( Figure 5C ). C21 efficiently inhibits the activation of Rac1 by Dock5-DHR2 in HEK293T cells ( Figure 5D ) but has no effect on Rac1 activation by the GEF TrioN (22) ( Figure 5E ). OC survival assays showed that C21 provokes OC death at concentrations above 25 µM ( Figure   5F ). 25 µM C21 efficiently inhibits the resorption of calcium-phosphate matrices (not shown) and bone resorption, as assessed by measurement of CTx concentration in the culture medium of OCs ( Figure 5G ). In parallel, control OCs grown in the presence of DMSO or 25 µM C21
were stained for TRAP to ascertain C21 was not toxic (not shown). Dose response experiment confirmed that C21 efficiently inhibits bone resoption by OCs in vitro ( Figure 5H ).
These results show that a small chemical compound preventing Rac1 activation by Dock5 efficiently suppresses bone resorption by OCs in vitro.
Dock5 deficiency leads to increased trabecular bone mass in mouse.
We explored the tissue distribution of Dock5 in mice. Interestingly, we found no activation of Dock5 transcription in the bone forming mature osteoblasts derived from MSCs ( Figure   6A ) while the expression of osteoblast differentiation marker genes showed a very strong increase ( Figure 6B ). Western blot analyses of protein extracts from a variety of mouse tissues showed that Dock5 is predominantly expressed in OCs, testis and placenta ( Figure   6C ). Although expressed in these latter tissues and in ovary (not shown), Dock5 -/mice breed normally (not shown), suggesting that Dock5 does not play an essential function in mouse reproduction. This shows that the expression of Dock5 is restricted to a very narrow set of tissues in mice, including bone degrading OCs and excluding bone forming osteoblasts.
Quantitative bone histomorphometry performed on histological slices revealed that trabecular bone volume to total volume ratio (BV/TV) is increased over 30% in Dock5 -/mice as compared to wild type animals: 19% ± 3.5 in Dock5 -/vs 14.3% ± 2.6 in Dock5 +/ + ( Figure   6D -E). In parallel, we found that OC number per bone surface (OC/mm) is identical in both genotypes: 11.2 ± 3.4 OC/mm in Dock5 -/vs 12.5 ± 3.4 Dock5 +/+ (Figure 6F -G).
Together with our in vitro observations, these data are consistent with an essential role of Dock5 for bone resorption but not for differentiation of OCs.
Discussion
Increased bone resorption by OCs is associated with various physiological disorders and pathological situations including hormonal defects, inflammation and cancer. Our study provides evidence that inhibition of Dock5 could be a novel approach to regulate bone loss.
Our data highlight the essential role of this atypical Rac1 exchange factor in bone resorption:
in the absence of Dock5, OCs differentiate but are unable to resorb bone due to their inability to form a sealing zone. We show that inhibition of Rac1 activation by Dock5 using a small chemical compound can modulate bone resorption. Finally, we found that Dock5 -/mice have increased trabecular bone mass associated with normal number of OCs, showing that Dock5 is also essential for bone resorption in vivo.
Targeting small GTPase signaling pathways using nitrogen containing bisphosphonates (N-BPs) has long proven an efficient strategy to control bone resorption by OCs in a variety of pathological situations (41) . N-BPs inhibit the C-terminal prenylation of small GTPases from the Ras, Rab and Rho families, inducing the accumulation of unprenylated small GTPases and provoking OC dysfunction and death (42) . However, N-BPs target a wide range of small GTPases that control many signaling cascades, which may be a reason for the undesirable side effects arising from N-BPs-based treatments (43, 44 Rho GTPases are well-established regulators of the actin cytoskeleton, which is highly dynamic in OCs, in particular during the resorption process when podosomes reorganize into a sealing zone (4,7). We showed that among the many RhoGEF genes expressed in OCs, only
Dock5 and the RhoA GEF Arhgef8 exhibit strong transcriptional activation during RANKL induced osteoclastogenesis (16) . We confirm now that the expression of Dock5 protein is indeed much higher in OC as compared to BMMs. In line with our findings, Ha et al. reported a quantitative proteomic study (17) showing that after ATP6v0d2, which is critical for OC 
Normal induction of the differentiation program suggests that the defects we observed in
Dock5 -/-OCs result from signaling defects, although we cannot exclude that important but as yet unidentified genes require Dock5 for their transcriptional activation during differentiation.
We found that the steady state activity of Rac1 is reduced in OCs lacking Dock5.
Interestingly, we also found reduced phosphorylation of p130Cas in the absence of Dock5. In OCs, M-CSF was shown to induce the stable interaction of c-Fms with !vß3 integrin and p130Cas. This leads to the phosphorylation of p130Cas, which is involved in the formation of the sealing zone (32) (33) (34) . Besides, Dock1 was shown to increase p130Cas phosphorylation and to positively regulate signaling from integrins to the p130Cas-Crk signaling complex (35) , which favors Rac1 activation (47,48). Altogether, this suggests that Dock5 and p130Cas could be involved in a common signaling network to control the activation of Rac1 in OCs.
Vav3 is also required for the formation of the sealing zone (31) . Nevertheless, our findings suggest that the signaling pathways controlled by Dock5 and Vav3 during this process are distinct. Indeed, M-CSF and adhesion stimulated activation of Rac1 requires Vav3 (31) whereas we found that it is independent of Dock5. M-CSF and adhesion were shown to activate Vav3, which is then recruited with Rac1 at the plasma membrane of OCs (49). We found that Dock5 associates with OC podosome belt. A possible hypothesis would be that Dock5 and Vav3 regulate Rac1 activation at distinct locations in OCs and at different phases of bone resorption cycle (Figure 7) . For efficient resorption, OCs alternate between spreading and resorption steps that involve disassembly and reformation of the sealing zone (7) . After the end of a resorption step, activation of c-Fms by M-CSF and of integrins through adhesion would recruit and activate Vav3 at the plasma membrane, leading to rapid activation of Rac1 (28, 49) . This would allow OC spreading and actin remodeling necessary for the initiation of new sealing zone formation ( Figure 7B ). Then, stable interaction of c-Fms with !vß3 by promoting the assembly of a signaling scaffold involving the p130Cas-CrkII complex (34) would sustain robust activation of Rac1 by Dock5 at the actin ring. This would allow the stabilization of the sealing zone necessary for efficient bone resorption ( Figure 7C ). and Dock1 (11) . Black background highlights residues conserved between the two sequences. 
